

EDITORIAL

'Too high, too low': The complexities of using thresholds in isolation to inform precautionary allergen ('may contain') labels

The disclosure of 'priority' allergens when present as an (intended) ingredient in foods is, in most countries, enshrined in legislation. However, the disclosure of unintended allergen presence (UAP) due to cross-contact or cross-contamination (e.g. through the use of shared production facilities) is not.¹ Many food businesses use precautionary allergen ('may contain') labels (PAL) to advise consumers as to the possibility of UAP; however, use of PAL is voluntary and not specifically regulated, and the presence/absence of PAL does not inform as to the actual level of risk that a particular food product might pose.² The use of PAL has significantly increased over the last decade,³ but because of the perception that they are used by food businesses to limit their own legal liability rather than convey useful information to consumers with food allergies and their caregivers, they are frequently ignored.⁴ Similarly, there is similar variation in interpretation of PAL by healthcare professionals, including allergy specialists.^{5,6} Most foods with a PAL statement do not contain detectable levels of the identified allergen, whilst some products without a PAL do have UAP, which can pose a significant risk of allergic reaction.^{3,7} A recent research prioritization exercise, undertaken by the UK Food Standards Agency and involving all relevant stakeholders (including consumers with food allergy, members of the general public, clinicians and researchers, representatives from the food industry and regulatory organizations), highlighted the need to improve use of PAL as a key priority, to allow consumers with food allergy to make informed decisions as to whether a food is 'safe' for purchase/consumption.⁸

In theory, the need for PAL could be informed by 'action levels': when the level of potential UAP is above a certain concentration (known as an action level), this would trigger the use of PAL; no PAL would be needed if levels were equal to or lower than this cut-off. Whilst some very dose-sensitive people might react to levels of allergen below the action level if a large amount of food containing UAP is consumed, risk could be mitigated in these individuals through risk communication (e.g. patient-specific advice to those who react to smaller amounts of allergen).⁹ Action levels have been developed based on *eliciting dose* (ED), the dose (mg) of total protein from the allergenic source predicted to provoke reactions in a defined proportion of the allergic population (e.g. ED₀₅ is the dose predicted to provoke reactions in 5% of the at-risk allergic population). Notably, single-dose challenges at an ED₀₅ level of exposure have been used to validate ED₀₅ values for peanut¹⁰ and cow's milk.¹¹

There have been attempts to improve the use of PAL through formal allergen risk assessment,¹² for example the Voluntary Incidental Trace Allergen Labelling (VITAL[®]) scheme established by the Allergen Bureau of Australia and New Zealand.¹³ However, the current lack of international consensus over use of PAL has led to a variety of regulatory approaches and increasing inconsistency in how food businesses use PAL, even between different member states of the European Union (EU).² To address this concern, the Codex Committee on Food Labelling, a committee of the Food and Agriculture Organization of the United Nations and World Health Organization (FAO/WHO), is currently evaluating the evidence over improving the use of PAL.

In this issue of allergy, Zuberbier et al. report a systematic review in which they sought to assess the number of fatal cases of anaphylaxis to exposures below 5 mg protein for food allergens. They found only 8 cases of fatal anaphylaxis reported in which the level of exposure could be estimated; there were no reported fatalities to levels of exposure below 5 mg protein.¹⁴ On the basis of these data, and a reasonable assumption that a portion size of 100 g is more typical than 1 000 g, the authors propose a cut-off of 0.5 mg food protein due to UAP per 100 g food (5 ppm) to inform whether PAL is needed.

The finding that no deaths have been reported to exposures under 5 mg protein is useful; however, the number of anaphylaxis fatalities is not a good indicator to define policy with respect to UAP and food safety, to prevent allergic reactions due to UAP. This is partly because more developed healthcare systems may be more effective at managing anaphylaxis, limiting morbidity and mortality. Using a very rare outcome (fatal anaphylaxis, in this case) to a common scenario (unintended allergen exposure) to define public health policy is not a good practice. We, therefore, have significant reservations over some of the proposed suggestions put forward by Zuberbier et al.

First, we recognize the allure of a straightforward approach, with a single analytical value applied across all food allergens and for all food product categories. The first iteration of the VITAL[®] scheme (VITAL-1) attempted a similar approach: a 'trigger' cut-off or action level (expressed in terms of a single concentration of allergen protein (ppm), independent of the serving size of food), above or below which PAL was or was not recommended.¹³ The ppm cut-offs were derived from using a food portion of 5 grams (equivalent to one Australian teaspoonful) as the reference quantity. The rationale was that the

TABLE 1 Estimated frequency of subjective and objective symptoms (including anaphylaxis) in allergic individuals with exposure to 5 ppm concentrations for different allergens and using estimated ED₀₅

Allergen	Expected rate of symptoms to a level of allergen exposure at 5 ppm (100 g serving)		Expected rate of symptoms to a level of allergen exposure at 5 ppm (250 g serving)		Expected rate of symptoms to an ED ₀₅ level of allergen exposure		Published cumulative ED ₀₅ (mg protein)				
	Any symptoms	Objective symptoms	Any symptoms	Objective symptoms	Any symptoms	Objective symptoms					
Peanut	~20%	Up to 1%	0.3 per 1000 (95%CI: 0.1 to 0.7)	Up to 3%	15%–25%	Up to 3%	5.6 per 1000 (95%CI: 2.4 to 13)	~25%	5%	2.3 per 1000 (95%CI: 1.0 to 5.1)	3.9
Cashew	5%–10%	Up to 5%	1.2 per 1000 (95%CI: 0.6 to 2.6)	Up to 9%	~30%	2.2 per 1000 (95%CI: 1.0 to 4.7)	2.2 per 1000 (95%CI: 1.0 to 4.7)	~30%	5%	2.5 per 1000 (95%CI: 1.1 to 5.3)	1.6
Hazelnut	~30%	Up to 3%	0.4 per 1000 (95%CI: 0.1 to 2.4)	Up to 5%	~40%	0.6 per 1000 (95%CI: 0.1 to 4)	0.6 per 1000 (95%CI: 0.1 to 4)	~50%	5%	1.2 per 1000 (95%CI: 0.2 to 7.9)	4.7
Walnut	Insufficient data	Up to 8%	1.9 per 1000 (95%CI: 0.7 to 4.6)	Up to 12%	~10%	2.7 per 1000 (95%CI: 1.0 to 6.5)	2.7 per 1000 (95%CI: 1.0 to 6.5)	~10%	5%	2.7 per 1000 (95%CI: 1.0 to 6.7)	1.2
Cow's Milk	10%	Up to 3%	0.7 per 1000 (95%CI: 0.3 to 1.7)	Up to 5%	10–15%	1.5 per 1000 (95%CI: 0.6 to 3.3)	1.5 per 1000 (95%CI: 0.6 to 3.3)	~20%	5%	2.5 per 1000 (95%CI: 1.1 to 5.5)	3.1
Egg	~5%	Up to 3%	0.3 per 1000 (95%CI: 0 to 11)	Up to 5%	~10%	0.5 per 1000 (95%CI: 0 to 17)	0.5 per 1000 (95%CI: 0 to 17)	~12%	5%	0.8 per 1000 (95%CI: 0 to 27)	2.4
Wheat	Not reported	Up to 1%	0.1 per 1000 (95%CI: 0 to 3.8)	Up to 3%	Not reported	0.2 per 1000 (95%CI: 0 to 7.5)	0.2 per 1000 (95%CI: 0 to 7.5)	Not reported	5%	1.1 per 1000 (95%CI: 0 to 38)	9.3
Fish	~10%	Up to 1%	Insufficient data	Up to 3%	~20%	Insufficient data	Insufficient data	~50%	5%	Insufficient Data	15.6
Shrimp	<1%	Up to 0.2%	Insufficient data	Up to 0.5%	~5%	Insufficient data	Insufficient data	~50%	5%	Insufficient Data	429

Note: ²³Maximum predicted rates for objective symptoms following exposure to 5 ppm allergen per 100 g and 250 g portion size estimated from Houben et al.²³ Data relating to frequency of any symptoms estimated from the literature.^{10,11,23–26} Rates of anaphylaxis to sED₀₅ exposures derived from Turner et al.²⁶

resulting action level would reflect the lowest amount of allergen in a small mouthful of food, which might cause a more dose-sensitive allergic individual to experience subjective symptoms. However, the use of a fixed food portion size (and hence a preset concentration) encountered significant criticism from consumers with food allergy, industry and government, for reasons including the following:

1. the data used to establish the trigger amounts of allergen protein were not—at the time—considered sufficiently robust, and
2. the use of a single concentration, based on a single portion size, meant that the system did not provide a consistent level of protection across different foods and food groups, and thus, the resulting PAL recommendation did not protect consumers of foods typically eaten in larger quantities. For example, serving sizes of 50g or 250g could contain 10 or 50 times the trigger amount of allergen per serving, respectively, before PAL was recommended.

These criticisms were then acted upon in subsequent iterations of VITAL (VITAL-2 and VITAL-3): the development of reference doses based on statistical dose-distribution modelling using a more extensive dataset of reaction thresholds reported in further clinical studies, and the introduction of reference amounts (amount of food eaten in a typical eating occasion) to inform the potential exposure level.¹³ Therefore, the proposal by Zuberbier et al. to return to a preset 5 ppm cut-off would seem to ignore the real-world experience obtained in VITAL-1 and represent a potential step backwards in providing meaningful PAL communication, which can be trusted by consumers.

Second, it can be very difficult to attribute cause and estimate consumption amounts in tragic cases of fatal anaphylaxis. Most of the literature identified by Zuberbier et al. describes reactions at food challenges, when the level of allergen exposure is known and patients are clinically well and without the presence of cofactors, which might

increase reaction severity.¹⁵ This is in stark contrast to allergic reactions occurring in the community. Unfortunately, Zuberbier et al. do not provide the overall number of fatal or life-threatening reactions included in their review nor the number of participants included in studies, so it is difficult to estimate the degree of uncertainty in their estimate. Indeed, they report only 8 cases of fatal anaphylaxis, a number which is less than the number of food-related fatal anaphylaxis cases in the United Kingdom in any one year,¹⁶ and probably less than the number occurring globally in any one month. So there is a very significant risk of under-reporting in the literature, which is a major limitation of their review. Whilst we truly hope no deaths have occurred to exposure amounts ≤ 5 mg, there has been at least one death reported in the literature where there might have been potential oral exposure below 5 mg.¹⁷ The risk of the approach of Zuberbier et al. is that it runs contrary to the accepted consensus that zero risk for food-allergic people is not a realistic or attainable option.¹⁸

Zuberbier et al. propose a PAL statement of ‘this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product’ as a voluntary declaration on pre-packed foods.¹⁴ This implies 5 ppm for the allergenic food, rather than total protein from that food (as stated in the review’s title) and highlights the need for consistent communication across all stakeholders: consumers, risk assessors, risk managers and healthcare professionals. The Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO) recommends expressing analytical results as ‘mg total protein of the allergenic food per kg food product’; we are concerned the similar but different wording proposed here will lead to confusion. Consumer surveys explicitly concur that a major limitation of PAL is the lack of a clear and short statement, which can be understood by consumers of all literary abilities. The phraseology proposed by Zuberbier et al. is certainly not clear or concise, nor does it accommodate the varying levels of literacy on the part of consumers.




FIGURE 1 Hierarchy of risks faced by people susceptible to IgE-mediated food allergy. Estimates refer to occurrence of allergic symptoms at ED_{05} levels of exposure in food-allergic individuals, using peanut as a reference allergy. Reproduced from Turner et al.²⁶ under a Creative Commons CC-BY license

Fourth, the assertion that a 5 ppm threshold 'can be readily detectable for all [14 EU priority] food allergens with the currently existing technology' is not uniformly true in practice.¹⁹ It should also be noted that detectable and quantifiable are not the same, and quantification will be needed for any risk-based regulatory/enforcement framework. Furthermore, the assertion does not even begin to take into consideration the impact of (1) particulate contamination (where the allergen (e.g. a nut fragment) is not equally distributed throughout the food but restricted to just one particular area of the food product, which may or may not be the part selected for analysis), and (2) food processing and matrix effects, which significantly reduce allergen detectability in some instances.^{20,21} Indeed, both the literature¹⁹ and a recent FAO/WHO expert panel concluded that whilst levels of allergen presence around a concentration of 5 ppm total protein of the allergenic food 'can be implemented and monitored to some degree with current analytical capabilities, [there remain] significant limitations in method performance'.²² It is for this reason that most experts recommend a quantitative risk assessment, which does not exclusively rely on analytical capabilities.

A 5 ppm cut-off unfairly restricts some allergens and food categories, resulting in a very over-conservative action level, whilst for others it leaves a higher-than-intended residual risk. Table 1 describes the proportion of individuals with food allergy who would be predicted to experience any/objective/anaphylaxis symptoms to a 5 ppm cut-off applied to a 100 g and 250 g serving portion, compared to using ED₀₅ reference doses.²³⁻²⁶ For some food groups, particularly seafood and spices, a 5 ppm cut-off would be overly restrictive, leading to a higher number of products with PAL than is necessary. For others, a significant proportion (greater than 10% for most allergens) would still have an objective allergic reaction, particularly at a 250 g serving portion—which is not unrealistic—and some would have anaphylaxis. Given these data, whilst at first glance a 5 ppm seems beneficial, in reality such an approach could inadvertently lead to more PAL, as many food businesses might conclude that the risks to health posed by a 5 ppm cut-off are too great, or the mitigation measures to comply with a 5 ppm cut-off are too difficult to achieve consistently in practice and, therefore, default to using PAL.

Finally—and most importantly—consumers with food allergy want more than just 'not to die'. Rather, they do not want to experience any allergic reaction. A 5 ppm cut-off would still mean that for some allergens, consumers would still experience symptoms (including anaphylaxis) (Table 1). These data demonstrate the hierarchy of symptoms that individuals with food allergy might experience to 5 ppm concentrations (Figure 1).²⁶ Given that zero risk is not a realistic or attainable option,¹⁸ there is a need to properly engage with food-allergic consumers as to the appropriate use and messaging over PAL.

We look forward to learning how the recent recommendations of the Ad Hoc Joint FAO/WHO Expert Consultation on Risk Assessment of Food Allergens are implemented at a global level, to better protect the consumers with food allergy.²² In the meantime, however well-intentioned, there is a risk that less-informed approaches may be counter-productive.

KEYWORDS

anaphylaxis, eliciting dose, food allergy, precautionary allergen labelling, reference dose, thresholds

ACKNOWLEDGEMENTS

None.

CONFLICTS OF INTEREST

The following authors are members of the EAACI Taskforce on Food allergen thresholds: K Beyer, P Comberati, G Konstantinou, ENC Mills, A Muraro, N Patel, B Remington, A Santos, S Schnadt, PJ Turner and B Vlieg-Boerstra. The following authors were members of the FAO/WHO Ad hoc Expert Consultation on Risk Assessment of Food Allergens: J Baumert, S Brooke-Taylor, R Crevel, G Houben, S La Vieille, ENC Mills, B Popping, B Remington, S Taylor and PJ Turner. Dr Turner reports personal fees from Aimmune Therapeutics, DBV Technologies, Allergenix, UK Food Standards Agency and ILSI Europe; grants from National Institute for Health Research (NIHR)/Imperial Biomedical Research Centre, UK Medical Research Council, UK Food Standards Agency, End Allergies Together and Jon Moulton Charity Trust, outside the submitted work. Dr Baumert reports personal fees from Neogen Corporation, outside the submitted work. Dr Beyer reports grants/research supports from Aimmune Therapeutics, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm and honoraria or consultation fees from Aimmune Therapeutics, Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis and Thermo Fisher outside of the submitted work. Dr Brooke-Taylor reports personal fees from The Allergen Bureau of Australia and New Zealand, outside the submitted work. Dr Crevel reports personal fees from Unilever Pensions, Food Allergy Research and Resource Program (University of Nebraska), Syngenta PLC, Upfield R&D BV, Zoetis LLC, Exponent Ltd., Fermenta SA, CEV SA, ILSI-Europe and other support from EAACI, outside the submitted work. Dr JO'B Hourihane receives research funding from NCR Ireland, City of Dublin Skin and Cancer Hospital, Temple St Hospital Foundation, Clemens von Pirquet Foundation, Aimmune Therapeutics, DBV Technologies and Johnson & Johnson. He is an advisory board member for Aimmune Therapeutics and receives speaker fees from DBV Technologies. He is a board member of the Irish Association of Allergy and Immunology and the Irish Food Allergy Network, which receive unrestricted grants and logistical support from industry sources for educational activities. Dr Konstantinou reports speaker fees and honoraria from Novartis. Dr Mills reports grants and other support from Reacta Biotech Ltd., grants from the European Food Safety Authority, Food Standards Agency and other support from the Biological and Biotechnological Sciences Research Council, Medical Research Council and Innovate UK, outside the submitted work. In addition, Dr Mills has a patent on blinding of allergens in foods for oral food challenges pending and was a founder director of Reacta Biotech and a member of the board until November 2019; she owns founder shares in the company. Dr Muraro reports speaker fees from Aimmune Therapeutics, DBV and Nestlé Purina and is an advisory board member/fees from Regeneron IDMC. Dr


Reese reports honoraria from AlbertZwei media GmbH, ALK-Abello Arzneimittel GmbH, Beiersdorf Dermo Medical GmbH, InfectoPharm Arzneimittel und Consilium GmbH, Leo Pharma GmbH, Nestlé Deutschland AG, Novartis Pharma GmbH, Nutricia Milupa GmbH and Sanomega GmbH outside of the submitted work. M. Said is Chief Executive Officer for Allergy & Anaphylaxis Australia, which reports grants from Bulla Family Dairy, Freedom Foods, Nestlé, NSW Food Authority, Mondelez, Nutricia, Abbott and Sweet William, and non-financial support from Nuts for Life, outside the submitted work. Dr Santos reports grants from Medical Research Council, Food Allergy Research and Education, Asthma UK, Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the NIHR Biomedical Research Centre award to Guy's and St Thomas' National Health Service Foundation Trust; consultancy fees from Thermo Scientific, Nutricia, InfoMed, Novartis and Buhlmann; consultancy fees from Allergy Therapeutics, Novartis, Iggenix and Stallergenes; and research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. S. Schnadt is employed by Deutscher Allergie- und Asthmabund e.V. (DAAB), a patient organization that has received industry support. Dr Taylor reports funding for research and industry outreach activities related to food allergens received from a consortium of more than 100 food processing companies. Dr Vlieg-Boerstra reports grants from Nutricia Research and personal fees from Nestlé, Nutricia and the Marfo Food Group. Dr Remington reports grants, personal fees, nonfinancial support from DBV Technologies and nonfinancial support from ILSI Europe, outside the submitted work and is an adjunct faculty member of the University of Nebraska. The other authors have no relevant conflicts of interest to declare.





AUTHOR CONTRIBUTIONS

PJT and BCR wrote the first draft of this manuscript, which was then revised, reviewed and approved by all authors.

FUNDING INFORMATION

NP and PJT are supported through The NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the authors and do not necessarily reflect those of the NHS, NIHR, the UK Departments of Health or Health Canada.

Paul J. Turner¹ 
 Joseph L. Baumert²
 Kirsten Beyer³
 Simon Brooke-Taylor⁴
 Pasquale Comberiati⁵
 René W. R. Crevel⁶
 Jennifer D. Gerdtts⁷
 M. Hazel Gowland⁸
 Geert F. Houben⁹
 Jonathan O'B. Hourihane¹⁰
 George N. Konstantinou¹¹
 Sébastien La Vieille¹²

Beatriz Moya¹³ 
 Antonella Muraro¹⁴
 E. N. Clare Mills¹⁵
 Nandinee Patel¹
 Marcia Podestà¹⁶
 Bert Popping¹⁷
 Imke Reese¹⁸ 
 Graham Roberts^{19,20} 
 Maria Said²¹
 Alexandra F. Santos²²
 Sabine Schnadt²³
 Steve L. Taylor²
 Berber Vlieg-Boerstra²⁴ 
 Benjamin C. Remington^{2,25}

the EAACI Taskforce on Food allergen thresholds

- ¹National Heart & Lung Institute, Imperial College London, London, UK
²Department of Food Science and Technology, Food Allergy Research and Resource Program, University of Nebraska, Lincoln, Nebraska, USA
³Department of Paediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
⁴Brooke-Taylor & Co Pty Ltd, Milawa, Victoria, Australia
⁵Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy
⁶René Crevel Consulting Limited, Bedford, UK
⁷Food Allergy Canada, Toronto, Ontario, Canada
⁸Allergy Action, St Albans, UK
⁹Netherlands Organisation for Applied Scientific Research TNO, Utrecht, The Netherlands
¹⁰Royal College of Surgeons in Ireland and Children's Health Ireland Temple St Hospital Dublin, Dublin, Ireland
¹¹Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece
¹²Food Directorate, Health Canada, Ottawa, Ontario, Canada
¹³Allergy Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
¹⁴Department of Woman and Child Health, Food Allergy Referral Centre Veneto Region, Padua University Hospital, Padua, Italy
¹⁵Division of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK
¹⁶Food Allergy Italia, Padua, Italy
¹⁷FOCOS-Food Consulting Strategically, Alzenau, Germany
¹⁸Nutrition Therapy, Munich, Germany
¹⁹NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton, UK
²⁰The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK

²¹Allergy & Anaphylaxis Australia, Castle Hill, Hornsby, New South Wales, Australia

²²Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, Children's Allergy Service, Evelina London, Guy's and St Thomas' Hospital, London, UK

²³Deutscher Allergie- und Asthmabund (DAAB), Mönchengladbach, Germany

²⁴Department of Paediatrics, OLVG Hospital, Amsterdam, The Netherlands

²⁵Remington Consulting Group BV, Utrecht, The Netherlands

Correspondence

Paul Turner, National Heart & Lung Institute, Imperial College London, Norfolk Place, London, W2 1PG, UK.

Email: p.turner@imperial.ac.uk

ORCID

Paul J. Turner  <https://orcid.org/0000-0001-9862-5161>

Beatriz Moya  <https://orcid.org/0000-0001-7730-2785>

Imke Reese  <https://orcid.org/0000-0001-8191-4020>

Graham Roberts  <https://orcid.org/0000-0003-2252-1248>

Berber Vlieg-Boerstra  <https://orcid.org/0000-0001-7962-5406>

REFERENCES

- Allen KJ, Turner PJ, Pawankar R, et al. Precautionary labelling of foods for allergen content: are we ready for a global framework? *World Allergy Organ J*. 2014;7(1):10.
- Madsen CB, van den Dungen MW, Cochrane S, et al. Can we define a level of protection for allergic consumers that everyone can accept? *Regul Toxicol Pharmacol*. 2020;117:104751.
- Hirst B. Reading Scientific Services Ltd. *Survey of Allergen Advisory Labelling and Allergen Content of UK Retail Pre-Packed Processed Foods*. Food Standards Agency (FSA) Project Code: FS241038. Available at: <http://www.food.gov.uk/science/research/allergy-research/fs241038>. Accessed xx Nov 2021.
- DunnGalvin A, Chan CH, Crevel R, et al. Precautionary allergen labelling: perspectives from key stakeholder groups. *Allergy*. 2015;70(9):1039-1051.
- Turner PJ, Skypala IJ, Fox AT. Advice provided by health professionals regarding precautionary allergen labelling. *Pediatr Allergy Immunol*. 2014;25(3):290-292.
- Turner PJ, Allen KJ, Mehr S, Campbell DE. Knowledge, practice, and views on precautionary allergen labeling for the management of patients with IgE-mediated food allergy – a survey of Australasian and UK healthcare professionals. *J Allergy Clin Immunol Pract*. 2016;4(1):165-167.
- Turner PJ, Kemp AS, Campbell DE. Advisory food labels: consumers with allergies need more than "traces" of information. *BMJ*. 2011;13(343):d6180.
- Turner PJ, Andoh-Kesson E, Baker S, et al. Identifying key priorities for research to protect the consumer with food hypersensitivity: a UK food standards agency priority setting exercise. *Clin Exp Allergy*. 2021;51(10):1322-1330.
- Graham F, Caubet JC, Eigenmann PA. Can my child with IgE-mediated peanut 164 allergy introduce foods labeled with "may contain traces"? *Pediatr Allergy Immunol*. 2020;31:601-607.
- Hourihane JO, Allen KJ, Shreffler WG, et al. Peanut allergen threshold study (PATS): novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy. *J Allergy Clin Immunol*. 2017;139(5):1583-1590.
- Turner PJ, d'Art YM, Duca B, et al. Single-dose oral challenges to validate eliciting doses in children with cow's milk allergy. *Pediatr Allergy Immunol*. 2021;32(5):1056-1065.
- DunnGalvin A, Roberts G, Schnadt S, et al. Evidence-based approaches to the application of precautionary allergen labelling: report from two iFAAM workshops. *Clin Exp Allergy*. 2019;49(9):1191-1200.
- Brooke-Taylor S, Christensen G, Grinter K, Sherlock R, Warren L. The allergen bureau VITAL program. *J AOAC Int*. 2018;101(1):77-82.
- Zuberbier T, Dörr T, Aberer W, et al. Proposal of 0.5mg of protein/100g of processed food as threshold for voluntary declaration of food allergen traces in processed food - a first step in an initiative to better inform patients and avoid fatal allergic reactions - A GA²LEN position paper. *Allergy*. 2021. [10.1111/all.15167](https://doi.org/10.1111/all.15167). Epub ahead of print.
- Turner PJ, Baumert JL, Beyer K, et al. Can we identify patients at risk of life-threatening allergic reactions to food? *Allergy*. 2016;71(9):1241-1255.
- Baseggio Conrado A, Ierodiakonou D, Gowland MH, Boyle RJ, Turner PJ. Food anaphylaxis in the United Kingdom: analysis of national data, 1998–2018. *BMJ*. 2021;17(372):n251.
- Foong RX, Turner PJ, Fox AT. Fatal anaphylaxis due to transcutaneous allergen exposure: an exceptional case. *J Allergy Clin Immunol Pract*. 2020;8(1):332-333.
- Madsen CB, Hattersley S, Allen KJ, et al. Can we define a tolerable level of risk in food allergy? report from a EuroPrevall/UK food standards agency workshop. *Clin Exp Allergy*. 2012;42(1):30-37.
- Holzhauser T, Johnson P, Hindley JP, et al. Are current analytical methods suitable to verify VITAL[®] 2.0/3.0 allergen reference doses for EU allergens in foods? *Food Chem Toxicol*. 2020;145:111709.
- Khuda S, Slate A, Pereira M, et al. Effect of processing on recovery and variability associated with immunochemical analytical methods for multiple allergens in a single matrix: dark chocolate. *J Agric Food Chem*. 2012;60(17):4204-4211.
- Khuda S, Slate A, Pereira M, et al. Effect of processing on recovery and variability associated with immunochemical analytical methods for multiple allergens in a single matrix: sugar cookies. *J Agric Food Chem*. 2012;60(17):4195-4203.
- Food and Agricultural Organization of the United Nations/World Health Organization. Summary report of the Ad hoc Joint FAO/WHO expert consultation on risk assessment of food allergens. part 2: review and establish threshold levels in foods of the priority allergens. 2021. Available at: https://cdn.who.int/media/docs/default-source/food-safety/jemra/2nd-allergen-summary-report-20aug2021.pdf?sfvrsn=915a8417_8. Accessed Nov, 2021.
- Houben GF, Baumert JL, Blom WM, et al. Full range of population eliciting dose values for 14 priority allergenic foods and recommendations for use in risk characterization. *Food Chem Toxicol*. 2020;146:111831.
- Blom WM, Vlieg-Boerstra BJ, Kruizinga AG, van der Heide S, Houben GF, Dubois AE. Threshold dose distributions for 5 major allergenic foods in children. *J Allergy Clin Immunol*. 2013;131(1):172-179.
- Ballmer-Weber BK, Fernandez-Rivas M, Beyer K, et al. How much is too much? Threshold dose distributions for 5 food allergens. *J Allergy Clin Immunol*. 2015;135(4):964-971.
- Turner PJ, Patel N, Ballmer-Weber BK, et al. Peanut can be used as a reference allergen for hazard characterization in food allergen risk management: a rapid evidence assessment and meta-analysis. *J Allergy and Clin Immunol Pract*. 2021;10(1):59-70. [10.1016/j.jaip.2021.08.008](https://doi.org/10.1016/j.jaip.2021.08.008)